Literature DB >> 23149977

Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector.

Andreia Gianotti Sommer1, Sarah S Rozelle, Spencer Sullivan, Jason A Mills, Seon-Mi Park, Brenden W Smith, Amulya M Iyer, Deborah L French, Darrell N Kotton, Paul Gadue, George J Murphy, Gustavo Mostoslavsky.   

Abstract

Through the ectopic expression of four transcription factors, Oct4, Klf4, Sox2 and cMyc, human somatic cells can be converted to a pluripotent state, generating so-called induced pluripotent stem cells (iPSCs)(1-4). Patient-specific iPSCs lack the ethical concerns that surround embryonic stem cells (ESCs) and would bypass possible immune rejection. Thus, iPSCs have attracted considerable attention for disease modeling studies, the screening of pharmacological compounds, and regenerative therapies(5). We have shown the generation of transgene-free human iPSCs from patients with different lung diseases using a single excisable polycistronic lentiviral Stem Cell Cassette (STEMCCA) encoding the Yamanaka factors(6). These iPSC lines were generated from skin fibroblasts, the most common cell type used for reprogramming. Normally, obtaining fibroblasts requires a skin punch biopsy followed by expansion of the cells in culture for a few passages. Importantly, a number of groups have reported the reprogramming of human peripheral blood cells into iPSCs(7-9). In one study, a Tet inducible version of the STEMCCA vector was employed(9), which required the blood cells to be simultaneously infected with a constitutively active lentivirus encoding the reverse tetracycline transactivator. In contrast to fibroblasts, peripheral blood cells can be collected via minimally invasive procedures, greatly reducing the discomfort and distress of the patient. A simple and effective protocol for reprogramming blood cells using a constitutive single excisable vector may accelerate the application of iPSC technology by making it accessible to a broader research community. Furthermore, reprogramming of peripheral blood cells allows for the generation of iPSCs from individuals in which skin biopsies should be avoided (i.e. aberrant scarring) or due to pre-existing disease conditions preventing access to punch biopsies. Here we demonstrate a protocol for the generation of human iPSCs from peripheral blood mononuclear cells (PBMCs) using a single floxed-excisable lentiviral vector constitutively expressing the 4 factors. Freshly collected or thawed PBMCs are expanded for 9 days as described(10,11) in medium containing ascorbic acid, SCF, IGF-1, IL-3 and EPO before being transduced with the STEMCCA lentivirus. Cells are then plated onto MEFs and ESC-like colonies can be visualized two weeks after infection. Finally, selected clones are expanded and tested for the expression of the pluripotency markers SSEA-4, Tra-1-60 and Tra-1-81. This protocol is simple, robust and highly consistent, providing a reliable methodology for the generation of human iPSCs from readily accessible 4 ml of blood.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149977      PMCID: PMC3499070          DOI: 10.3791/4327

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  11 in total

1.  Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells.

Authors:  Tomohisa Seki; Shinsuke Yuasa; Mayumi Oda; Toru Egashira; Kojiro Yae; Dai Kusumoto; Hikari Nakata; Shugo Tohyama; Hisayuki Hashimoto; Masaki Kodaira; Yohei Okada; Hiroyuki Seimiya; Noemi Fusaki; Mamoru Hasegawa; Keiichi Fukuda
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

Review 2.  Induced pluripotency: history, mechanisms, and applications.

Authors:  Matthias Stadtfeld; Konrad Hochedlinger
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

3.  Reprogramming of human peripheral blood cells to induced pluripotent stem cells.

Authors:  Judith Staerk; Meelad M Dawlaty; Qing Gao; Dorothea Maetzel; Jacob Hanna; Cesar A Sommer; Gustavo Mostoslavsky; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

4.  The majority of the in vitro erythroid expansion potential resides in CD34(-) cells, outweighing the contribution of CD34(+) cells and significantly increasing the erythroblast yield from peripheral blood samples.

Authors:  Emile van den Akker; Timothy J Satchwell; Stephanie Pellegrin; Geoff Daniels; Ashley M Toye
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

5.  Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette.

Authors:  Aba Somers; Jyh-Chang Jean; Cesar A Sommer; Amel Omari; Christopher C Ford; Jason A Mills; Lei Ying; Andreia Gianotti Sommer; Jenny M Jean; Brenden W Smith; Robert Lafyatis; Marie-France Demierre; Daniel J Weiss; Deborah L French; Paul Gadue; George J Murphy; Gustavo Mostoslavsky; Darrell N Kotton
Journal:  Stem Cells       Date:  2010-10       Impact factor: 6.277

6.  Generation of human induced pluripotent stem cells from dermal fibroblasts.

Authors:  W E Lowry; L Richter; R Yachechko; A D Pyle; J Tchieu; R Sridharan; A T Clark; K Plath
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-15       Impact factor: 11.205

7.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

8.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

9.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

10.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

View more
  38 in total

Review 1.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives.

Authors:  Alexander E Berezin
Journal:  World J Diabetes       Date:  2014-12-15

3.  Efficient iPS cell generation from blood using episomes and HDAC inhibitors.

Authors:  Jesse J Hubbard; Spencer K Sullivan; Jason A Mills; Brian J Hayes; Beverly J Torok-Storb; Aravind Ramakrishnan
Journal:  J Vis Exp       Date:  2014-10-28       Impact factor: 1.355

4.  Protocol for Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) to a Hepatic Lineage.

Authors:  Joseph E Kaserman; Andrew A Wilson
Journal:  Methods Mol Biol       Date:  2017

Review 5.  Revisiting Mitochondrial Function and Metabolism in Pluripotent Stem Cells: Where Do We Stand in Neurological Diseases?

Authors:  Carla Lopes; A Cristina Rego
Journal:  Mol Neurobiol       Date:  2016-02-18       Impact factor: 5.590

6.  High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia.

Authors:  Spencer K Sullivan; Jason A Mills; Sevasti B Koukouritaki; Karen K Vo; Randolph B Lyde; Prasuna Paluru; Guoha Zhao; Li Zhai; Lisa M Sullivan; Yuhuan Wang; Siddharth Kishore; Eyad Z Gharaibeh; Michele P Lambert; David A Wilcox; Deborah L French; Mortimer Poncz; Paul Gadue
Journal:  Blood       Date:  2013-12-13       Impact factor: 22.113

7.  Generation of Induced Pluripotent Stem Cells from Frozen Buffy Coats using Non-integrating Episomal Plasmids.

Authors:  Viviana Meraviglia; Alessandra Zanon; Alexandros A Lavdas; Christine Schwienbacher; Rosamaria Silipigni; Marina Di Segni; Huei-Sheng Vincent Chen; Peter P Pramstaller; Andrew A Hicks; Alessandra Rossini
Journal:  J Vis Exp       Date:  2015-06-05       Impact factor: 1.355

Review 8.  Can stem cells be used to generate new lungs? Ex vivo lung bioengineering with decellularized whole lung scaffolds.

Authors:  Darcy E Wagner; Ryan W Bonvillain; Todd Jensen; Eric D Girard; Bruce A Bunnell; Christine M Finck; Andrew M Hoffman; Daniel J Weiss
Journal:  Respirology       Date:  2013-08       Impact factor: 6.424

9.  A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput electrophysiological analyses of human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Angelica Lopez-Izquierdo; Mark Warren; Michael Riedel; Scott Cho; Shuping Lai; Robert L Lux; Kenneth W Spitzer; Ivor J Benjamin; Martin Tristani-Firouzi; Chuanchau J Jou
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-29       Impact factor: 4.733

10.  A candidate transacting modulator of fetal hemoglobin gene expression in the Arab-Indian haplotype of sickle cell anemia.

Authors:  Vinod Vathipadiekal; John J Farrell; Shuai Wang; Heather L Edward; Heather Shappell; A M Al-Rubaish; Fahad Al-Muhanna; Z Naserullah; A Alsuliman; Hatem Othman Qutub; Irene Simkin; Lindsay A Farrer; Zhihua Jiang; Hong-Yuan Luo; Shengwen Huang; Gustavo Mostoslavsky; George J Murphy; Pradeep K Patra; David H K Chui; Abdulrahman Alsultan; Amein K Al-Ali; Paola Sebastiani; Martin H Steinberg
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.